Puma Biotechnology Inc. (PBYI)

NASDAQ: PBYI · IEX Real-Time Price · USD
3.19
0.00 (0.00%)
At close: Aug 18, 2022 4:00 PM
3.12
-0.07 (-2.19%)
After-hours: Aug 18, 2022 7:41 PM EDT
0.00%
Market Cap 145.32M
Revenue (ttm) 206.86M
Net Income (ttm) -34.48M
Shares Out 45.56M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE 10.98
Dividend n/a
Ex-Dividend Date n/a
Volume 131,408
Open 3.16
Previous Close 3.19
Day's Range 3.10 - 3.23
52-Week Range 1.60 - 7.84
Beta 0.66
Analysts Sell
Price Target 5.51 (+72.7%)
Earnings Date Aug 4, 2022

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive soli... [Read more...]

Industry Biotechnology
Founded 2010
Employees 196
Stock Exchange NASDAQ
Ticker Symbol PBYI
Full Company Profile

Financial Performance

In 2021, PBYI's revenue was $253.16 million, an increase of 12.46% compared to the previous year's $225.11 million. Losses were -$29.13 million, -51.45% less than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PBYI stock is "Sell." The 12-month stock price forecast is 5.51, which is an increase of 72.73% from the latest price.

Price Target
$5.51
(72.73% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human p...

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma's Board of Directors approved the...

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 950% and 11.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotechnology Reports Second Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will release its earnings results for 2Q-2022 and host a conference call to discuss results on Aug. 4, 2022.

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 2Q-2022 financial results and host a conference call after market close on Aug. 4, 2022.

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 An...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented results from its SUMMIT Trial, Metastatic Breast Cancer, in a poster presentation at ASCO 2022.

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket' Trial of Nerat...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented Biliary Tract Cancer results from its SUMMIT Trial in a poster presentation at ASCO 2022.

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Abstracts for two posters to be presented by Puma Biotechnology at the 2022 ASCO Annual Meeting in June are now posted on the ASCO.org website.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

Puma Biotech (PBYI) Reports Q1 Loss, Misses Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 38.46% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotechnology Reports First Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)--On May 5, 2022, Puma Biotechnology issued its financial results for the first quarter ended March 31, 2022, and hosted a call following the release.

Puma Biotech (PBYI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the titles of two abstracts for neratinib poster presentations at the ASCO 2022 Annual Meeting in June.

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--On May 5, 2022, Puma Biotechnology will host a conference call to discuss financial results for the first quarter ended March 31, 2022.

Puma Biotechnology Announces $10 Million Private Placement

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the sale in a private placement of 3,584,228 shares of its common stock at $2.79 per share.

Puma Biotechnology to Participate in Breast Cancer Panel at Cowen's Annual Health Care Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO Alan Auerbach will participate in a Breast Cancer Panel at 2:10 pm ET on March 9 at Cowen's 42nd Annual Health Care Conference.

Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y

Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.

Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued financial results for the fourth quarter and year ended Dec. 31, 2021, followed by a call to discuss operating results.

Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 pm PST on March 3 to review its fourth quarter and full year 2021 financial results.

Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biote...

Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's neratinib (NERLYNX) therapy and dose escalation are included in the updated NCCN Guidelines for the treatment of breast cancer .

Puma Biotechnology Releases Updated Corporate Presentation

LOS ANGELES--(BUSINESS WIRE)--On January 10, 2022, Puma Biotechnology released an updated corporate presentation.